Review

Subject Category: Review Article

British Journal of Pharmacology (2007) 151, 737–748; doi:10.1038/sj.bjp.0707253; published online 30 April 2007

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

P K Gillman1

1PsychoTropical Research, Bucasia, Queensland, Australia

Correspondence: Dr PK Gillman, PsychoTropical Research, PO Box 86, Bucasia, Queensland 4750, Australia. E-mail: kg@matilda.net.au or kg@caliph.net.au

Received 23 January 2007; Revised 26 February 2007; Accepted 26 February 2007; Published online 30 April 2007.

Top

Abstract

New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful. The relative toxicity of TCAs continues to be more precisely defined, as do TCA interactions with selective serotonin reuptake inhibitors (SSRIs). TCA interactions with monoamine oxidase inhibitors (MAOIs) have been, historically, an uncertain and difficult question, but are now well understood, although this is not reflected in the literature. The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs. Clomipramine is the only available antidepressant drug that has good evidence of clinically relevant serotonin and noradrenaline reuptake inhibition (SNRI). These data assist drug selection for monotherapy and combination therapy and predict reliably how and why pharmacodynamic and pharmacokinetic interactions occur. In comparison, two newer drugs proposed to have SNRI properties, duloxetine and venlafaxine, may have insufficient NRI potency to be effective SNRIs. Combinations such as sertraline and nortriptyline may therefore offer advantages over drugs like venlafaxine that have fixed ratios of SRI/NRI effects that are not ideal. However, no TCA/SSRI combination is sufficiently safe to be universally applicable without expert knowledge. Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings.

Keywords:

antidepressive agents, serotonin noradrenaline uptake inhibitors, drug combinations, drug–drug interactions, serotonin toxicity, tyramine pressor test, monoamine oxidase inhibitors

Abbreviations:

CYP450, cytochrome P450 enzymes; HCR, human cloned receptor; NAT, noradrenaline transporter; PM, IM, UM, poor, intermediate, ultrarapid, metabolizer; SERT, serotonin transporter; SS, serotonin syndrome; ST, serotonin toxicity; (S)SRIs, selective serotonin reuptake inhibitors; (S)NRIs, serotonin and noradrenaline reuptake inhibitors; TCAs, tricyclic antidepressants; TYR30, pressor response to tyramine

Top

MORE ARTICLES LIKE THIS

Extra navigation

.

natureproducts


ADVERTISEMENT